<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-133837</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients</dc:title>
<dc:description xml:lang="en">Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn´s disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related to complex pharmacokinetics of infliximab. Aims: To explore optimal dosing strategies of infliximab in treatment-naïve patients with ulcerative colitis through predictive Monte Carlo simulations based on a validated population PK model. Methods: A population of 2,000 treatment-naïve patients was generated by Montecarlo simulation. Six dosing strategies for maintenance therapy were simulated on this population. Strategies 1 and 2 consisted on 5 mg/kg and 6 mg/kg doses, respectively, and 8 weeks inter-dose interval. Strategies 3 and 4 used Individualized doses, adjusted to albumin level, sex and body weight, and a fix interdose interval of 8 weeks to achieve a target trough concentration of 5 mg/L or 6 mg/L, respectively.  Strategies 5 and 6 used a fix dose of 5 mg/kg and individualized inter-dose intervals, adjusted to the same covariates, to achieve a target concentration, of 5 mg/L or 6 mg/L, respectively. Results: Strategies 2-6 reached trough levels statistically higher than strategy 1 (p &lt; 0.05). Strategy 5 proved to be the best dosing strategy. It was associated with a higher proportion of responder patients than strategy 1 (62 % vs. 40 %) without reaching higher peak concentrations. Conclusions: Optimization of maintenance treatment of colitis with infliximab by a pharmacokinetic approach could benefit infliximab-naive patients with ulcerative colitis (AU)</dc:description>
<dc:creator>Ferriols-Lisart, Rafael</dc:creator>
<dc:creator>Mínguez-Pérez, Miguel</dc:creator>
<dc:creator>Alós-Almiñana, Manuel</dc:creator>
<dc:creator>Pérez-Pitarch, Alejandro</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Rev Esp Enferm Dig;107(3): 137-142, mar. 2015. tab, graf</dc:source>
<dc:identifier>ibc-133837</dc:identifier>
<dc:title xml:lang="es">Aproximación al diseño de un programa de administración de infliximab a pacientes con colitis ulcerosa basado en un modelo famacocinético</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d23971^s22057</dc:subject>
<dc:subject>^d28380</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d54063^s22079</dc:subject>
<dc:type>article</dc:type>
<dc:date>201503</dc:date>
</metadata>
</record>
</ibecs-document>
